版本:
中国

BRIEF-Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions

March 7 Regeneron Pharmaceuticals Inc

* Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions

* Regeneron Pharmaceuticals Inc says effect of praluent on cardiovascular (CV) morbidity and mortality has not yet been determined Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐